Sat, Dec 27, 2014, 6:56 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • cosmicgene cosmicgene Dec 20, 2013 2:24 PM Flag

    My take on this - Buyout

    I am a newbie to this stock, but not to Biotech stocks. The compounds are good and in fact really the best for lung. Pipeline is fantastic and my doctors like it.

    They have cash flow issues and coulnd't sponsor the trials needed to bring the drug to the market.

    Observe the events:
    1) Insiders bought huge amount of offering and loaded up.
    2) Got the guy who knows how to stage and company and sell it off (Biotech realtor)
    3) Fantastic compounds that are farther along the line and robust pipeline.

    Expect a buyout in few weeks/months around $11....

    I spoke to couple of doctors who saw the data and they said it is a clear winner....

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Best for lung? You're kidding, right? Why the selloff after GALAXY-1 results?

      1) Insiders have bought huge amounts of shares at each offering over the last 3+ years. So nothing special.
      2) What guy are you talking about? Steven Bernitz? If so what companies has he staged and sold off?
      3) There are not any other compounds further along the line, nor do they have a robust pipeline at this time. Ganetespib is it, plain and simple.

      Finally, it's breast cancer treatment not lung cancer that holds more promise for patients and in turn shareholders. Unfortunately, the company has stated that ENCHANT-2 is contingent on a partnership.

      So your expected buyout timeline and price target is ridiculous.

      I've seen many, many posters like you over the last 3+ years of being in and out of this stock. They make incorrect statements, predict stock prices/buyouts/partnerships/trial results, etc. etc. then disappear when they're wrong.

      • 1 Reply to syenfrout
      • On target once again Syenfout. Breast cancer is the most promising area for Ganetespib, but it is very early stage. We need to see some data for higher numbers of patients with Ganetespib as monotherapy, and perhaps more importantly, in combination with Paclitaxel. Management makes me angry with their incompetence. The Galaxy-1 and 2 Lung cancer trials are still viable, but the chances for success have been reduced. In any event. we will know more about Galaxy-1 in a few months when the final data comes in. Funny how that pumper Ivan has disappeared.

    • Interesting observations. I also notice from some of your other posts you play with ARIA. Congrats on the nice run.

      My take... a partnership is more likely and a possible buyout at some point during 2014.

    • Agree on your 3 pts. above. It all looks good for SNTA. BTW, what a beautiful green day we are having. Merry Christmas Longs!
      GLTAL's

      Sentiment: Strong Buy

 
SNTA
2.61-0.02(-0.76%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.